GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo

Chang YING1, Bo-duan XIAO1, Yun QIN1, Bin-rong WANG1, Xin-yuan LIU1,2, Ru-wei WANG3, Ling FANG3, Hui YAN4, Xiu-mei ZHOU1, Yi-gang WANG1
1 Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences Zhejiang Sci-Tech University, Hangzhou 310018, China
2 Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
3 Zhejiang Conba Pharmaceutical Co., Ltd, Hangzhou 310018, China
4 Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
Correspondence to: Yi-gang WANG:,
DOI: 10.1038/aps.2017.91
Received: 28 March 2017
Accepted: 5 June 2017
Advance online: 7 September 2017


GOLPH2 (also called GP73) is a Golgi glycoprotein, which has been identified as a novel tumor marker upregulated in various cancers, including prostate cancer (PCa). GD55 is a novel GOLPH2-regulated oncolytic adenovirus that exhibits a strong killing effect on hepatoma cells. Here, we investigate the antitumor effect of GD55 on prostate cancer stem cell (CSC)-like cells in vitro and in vivo. Prostate CSC-like sphere cells were acquired and enriched by culturing DU145, LNCap or P3 prostate cancer cells in suspension. The prostate CSC-like sphere cells were capable of self-renewal, differentiation and quiescence, displaying tumorigenic feature and chemo-resistance to 5-FU, doxorubicin and DDP. Treatment with GD55 (1, 5, 10 MOI) dose-dependently suppressed the viability of DU145 sphere cells, which was a more pronounced compared to its cytotoxic action on the parental DU145 cells. In a mouse xenograft prostate CSC-like model, intratumoral injection of GD55 markedly suppressed the growth rate of xenograft tumors and induced higher levels of cell death and necrosis within the tumor tissues. Our results demonstrate that GD55 infection exerts strong anticancer effects on prostate CSC-like cells in vitro and in vivo, and has a potential to be used in the clinical therapy of PCa.
Keywords: prostate cancer; cancer stem cells; GOLPH2; oncolytic adenovirus; GD55; antitumor agents; cancer targeting genevirotherapy

Article Options

Download Citation

Cited times in Scopus